Patent issued in japan bolsters ip protection for jaguar health in the treatment of short bowel syndrome (sbs)

New patent issued to napo pharmaceuticals, a jaguar health family company, for core rare disease target indication for crofelemer jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of sbs and microvillus inclusion disease in the us, eu, and middle east/north africa regions, with results expected before the end of 2023 and in 2024 san francisco, ca / accesswire / september 13, 2023 / napo pharmaceuticals (napo), a jaguar health (nasdaq:jagx) (jaguar) family company, today announced that the japan patent office has issued a new japan patent to napo for methods for treating short bowel syndrome (sbs), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, napo's novel plant-based prescription drug. "we are very pleased that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of sbs," said steven king ph.d.
JAGX Ratings Summary
Quant
JAGX Quant Ranking
Sector
Industry
Quant Rating
Quant Score